Roles for Chemokines in Liver Disease

Slides:



Advertisements
Similar presentations
Inflammation and Cancer
Advertisements

Don C. Rockey  Clinical Gastroenterology and Hepatology 
M1 – Immunology CYTOKINES AND CHEMOKINES March 26, 2009 Ronald B
Peter J. Barnes, FRS, FMedSci 
Oxidants and antioxidants in alcohol-induced liver disease
Mononuclear phagocytes in Immune Defence
Bin Gao, Hidekazu Tsukamoto  Gastroenterology 
Abhishek Chauhan, David H. Adams  Gastroenterology 
The inflammasome in liver disease
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Obesity, inflammation, and liver cancer
Inflammation and Colon Cancer
Oxidants and antioxidants in alcohol-induced liver disease
Don C. Rockey  Clinical Gastroenterology and Hepatology 
Peter J. Barnes, FRS, FMedSci 
Nonalcoholic steatohepatitis
Microbial Influences in Inflammatory Bowel Diseases
The Th17 immune response in renal inflammation
Volume 49, Issue 5, Pages (November 2008)
Nat. Rev. Cardiol. doi: /nrcardio
Tumor necrosis factor: Biology and therapeutic inhibitors
Mark A. Schroeder, Jaebok Choi, Karl Staser, John F. DiPersio 
Mechanisms of Hepatic Fibrogenesis
Biology and Clinical Applications of Pancreatic Cancer Stem Cells
Mesenchymal Cells in Colon Cancer
Benoit Chassaing, Arlette Darfeuille–Michaud  Gastroenterology 
Macrophage heterogeneity, phenotypes, and roles in renal fibrosis
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
The Multitasking Organ: Recent Insights into Skin Immune Function
Bhagelu Ram Achyut, Li Yang  Gastroenterology 
Inflammation and portal hypertension – The undiscovered country
From immunosuppression to tolerance
Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer  Ilya Gukovsky, Ning Li, Jelena Todoric,
Warren Strober, Ivan J. Fuss  Gastroenterology 
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Inflammatory and immune cells involved in chronic obstructive pulmonary disease (COPD). Inflammatory and immune cells involved in chronic obstructive pulmonary.
The Multitasking Organ: Recent Insights into Skin Immune Function
Volume 146, Issue 5, Pages (May 2014)
Volume 140, Issue 2, Pages e4 (February 2011)
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Figure 6 Innate lymphoid cells in liver inflammation
Obesity, Inflammation, and Insulin Resistance
Pro-endometriotic niche in endometriosis
Celiac Disease: From Pathogenesis to Novel Therapies
The Origins and Drivers of Insulin Resistance
Hepatic fibrosis: Concept to treatment
Volume 134, Issue 4, Pages (April 2008)
Veronika Lukacs-Kornek, Detlef Schuppan  Journal of Hepatology 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Percy A. Knolle, Robert Thimme  Gastroenterology 
Chengcheng Jin, Jorge Henao-Mejia, Richard A. Flavell  Cell Metabolism 
Braedon McDonald, Paul Kubes  Gastroenterology 
Volume 144, Issue 3, Pages (March 2013)
Herbert Tilg, Gökhan S. Hotamisligil  Gastroenterology 
Inflammation and Lipid Signaling in the Etiology of Insulin Resistance
Macrophages in Tissue Repair, Regeneration, and Fibrosis
A New “Immunological” Role for Adipocytes in Obesity
Volume 142, Issue 4, Pages e6 (April 2012)
Macrophage heterogeneity in liver injury and fibrosis
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Christoph Becker, Alastair J. Watson, Markus F. Neurath 
Figure 4 Role of chemokines in dendritic cell migration
Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation
Chemokines: Key Players in Innate and Adaptive Immunity
Shih-Yen Weng, Detlef Schuppan  Journal of Hepatology 
Sander Lefere, Frank Tacke  JHEP Reports 
Macrophages, Immunity, and Metabolic Disease
Tumor necrosis factor: Biology and therapeutic inhibitors
Peter J. Barnes, FRS, FMedSci 
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Presentation transcript:

Roles for Chemokines in Liver Disease Fabio Marra, Frank Tacke  Gastroenterology  Volume 147, Issue 3, Pages 577-594.e1 (September 2014) DOI: 10.1053/j.gastro.2014.06.043 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Important chemokine pathways for the initiation of liver inflammation. Resident hepatic macrophages, Kupffer cells, are an important sensor of tissue injury. They become activated via pathogen-associated molecular patterns (PAMPs) from invading pathogens, by danger-associated molecular patterns (DAMPs) released from injured hepatocytes and cholangiocytes, and by stellate cells that also respond to danger signals. On activation, Kupffer cells release proinflammatory cytokines (TNF, IL-1) and chemokines (CXCL1, CXCL2, CXCL8, CXCL16, CCL2), which initiate the acute phase response, attract neutrophils (via CXCR1/CXCR2) that release cytotoxic and antimicrobial molecules (reactive oxygen species [ROS], oxidants, defensins), NKT cells (via CXCR6) that in turn perpetuate inflammatory responses via proinflammatory cytokines (TNF, IFN-γ), and inflammatory monocytes (via CCR2) that differentiate into proinflammatory hepatic macrophages. The figure represents a selection among the manifold immune cell subsets and chemokine pathways involved in the initiation of liver inflammation or injury. Gastroenterology 2014 147, 577-594.e1DOI: (10.1053/j.gastro.2014.06.043) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 (A) Chemokines in the pathogenesis of fatty liver and nonalcoholic steatohepatitis. In the AT, obesity leads to recruitment of monocytes from the bloodstream, predominantly via CCL2/CCR2. Within AT, macrophages undergo a phenotypic switch from an anti-inflammatory, M2 state to proinflammatory M1. CXC chemokines such as CXCL2 contribute to neutrophil recruitment, whereas others, including CCL20, increase the inflow of T lymphocytes. These changes result in AT insulin resistance, adipokine imbalance, and flow of lipotoxic free fatty acids (FFA) to the liver. These changes contribute to determine hepatic fatty degeneration, activation of Kupffer cells, which together with hepatocytes and stellate cells amplify inflammation via chemokines (CCL2 and CCL5), and recruitment of immune cells (eg, monocytes) into the liver. Chemokines have also been directly implicated in the accumulation of lipids within hepatocytes. (B) Chemokines in the pathogenesis of alcohol-related injury. Different CXC chemokines, particularly CXCL8, mediate recruitment of neutrophils, which contribute to tissue damage. CCL20, a ligand of CCR6, mediates inflammation and promotes fibrogenesis. In addition, CCL20 mediates the effects of LPS. CCL2 also contributes to inflammation, fibrosis, and possibly steatosis. Proinflammatory chemokines are mostly secreted by M1 macrophages, which may be counteracted and inhibited by M2-polarized cells. Gastroenterology 2014 147, 577-594.e1DOI: (10.1053/j.gastro.2014.06.043) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Important chemokine pathways for the progression and regression of liver fibrosis. The scheme summarizes relevant chemokine-mediated actions of immune cell subset recruitment, interactions with parenchymal and nonparenchymal liver cells, and functionality in the context of progressing or regressing liver fibrosis, mainly based on experimental mouse models. Details are explained in the main text. Gastroenterology 2014 147, 577-594.e1DOI: (10.1053/j.gastro.2014.06.043) Copyright © 2014 AGA Institute Terms and Conditions

Figure 4 Chemokines and HCC. CXCL8 mediates recruitment of neutrophils, which favor invasion through secretion of matrix metalloproteinase 9 (MMP-9). In addition, CXCL8 regulates angiogenesis and the biology of tumor-initiating cells. CXCL8 and other CXC chemokines also directly stimulate growth of cancer cells. CXCL12 is involved in cancer growth and metastasis and contributes to the biology of tumor-initiating cells. CC chemokines regulate leukocyte trafficking, This includes CD8 T cells and NK cells, which exert antitumor effects, and regulatory T cells, which mediate immune evasion. Similarly, recruited tumor-associated macrophages may create an inflammatory antitumor environment or mediate immune suppression. Gastroenterology 2014 147, 577-594.e1DOI: (10.1053/j.gastro.2014.06.043) Copyright © 2014 AGA Institute Terms and Conditions

Supplementary Figure 1 Approaches to pharmacological interference with the chemokine system. (A) The interaction between a chemokine and a chemokine receptor is schematically shown. Modulation of chemokine signaling may be obtained by interfering with ligand binding with monoclonal antibodies (B) against the chemokine or (C) against the receptor. (D) Receptor antagonists prevent the occupation of the receptor by the ligand. (E) The abundance of the ligand may be reduced by the use of aptamers, such as oligonucleotides. (F) Small molecule inhibitors may prevent transmission of the signal downstream of the chemokine receptor. (G) Finally, truncated forms of chemokine ligands may work as receptor antagonists or partial agonists. Gastroenterology 2014 147, 577-594.e1DOI: (10.1053/j.gastro.2014.06.043) Copyright © 2014 AGA Institute Terms and Conditions